Mesothelioma is a disease of pleural cells lining the lungs which is often caused by exposure to asbestos. The molecular mechanism(s) that regulate the transformation of pleural mesothelioma cells to a migratory and malignant phenotype are unclear. In recent work published in this journal, Laszlo et al performed a set of elegant experiments to identify a key molecular mechanism that may explain the aggressive nature of this disease. Using patient-derived mesothelioma cells with high versus low migratory activity, the authors conducted a genome-wide expression analysis. They identified a significant reduction in ITGA7 expression only in highly migratory malignant pleural mesothelioma cells and showed that loss of ITGA7 expression was associated with methylation of the promoter. Forced expression of integrin 7 reversed the migratory phenotype of these cells. Finally, the authors identified a strong correlation between ITGA7 expression and patient survival. Together, these results identify expression of integrin 7 as a molecular mechanism for the aggressive migratory transformation of mesothelioma and identify a potentially novel diagnostic and therapeutic target.
Introduction
Mesothelioma is a disease of the pleural cells lining the lung often caused by exposure to asbestos and treatment usually involves surgical intervention. Malignant pleural mesothelioma is often refractory to surgery, due to the recurrence of tumour growth, with median survival times of 9-12 months [1] . During the transition to the malignant form, pleural mesothelioma cells become substrate-independent and highly migratory. The molecular pathways that regulate this transition are poorly understood. Laszlo et al [1] performed genome-wide transcriptome analysis to identify changes in gene expression associated with the migratory phenotype of pleural mesothelioma cells. They identified 139 genes that were differentially expressed in highly motile cells. Abundance of ITGA7 transcript, a known tumor suppressor, was greatly reduced in highly motile malignant pleural mesothelioma cells [1] .
Integrin 7 in disease and as a tumour suppressor
Integrin α7 chain (encoded by ITGA7) pairs with the β1 integrin chain to form the α7β1 integrin heterodimer, a major laminin receptor found in many tissues [2] . Mutations in the integrin α7 gene cause congenital myopathy in patients and mice [3] [4] [5] , and α7β1 integrin is a major modifier of disease progression in mouse models and patients with muscular dystrophy [6] [7] [8] . Although the majority of studies on integrin α7 have focused on skeletal muscle, there is increasing evidence that this integrin acts as a powerful tumour suppressor in many forms of cancer. This activity appears to reside with the adhesive properties of α7β1 integrin, which serves as a 'molecular glue', reducing the metastatic potential of tumour cells. Mutations in the ITGA7 gene that result in reduced levels of α7β1 integrin have been identified in prostate cancers, hepatocellular carcinomas, glioblastomas, and leiomyosarcomas [9] . Associated with loss of integrin α7 are changes in cell signalling pathways associated with malignancy including increased cell growth and motility. These observations indicate that integrin α7 can act to regulate cell mobility, tumour growth, and transition to metastasis, and as such, serves as a major tumour suppressor in many cancers.
In recent work published in The Journal of Pathology, Laszlo et al [1] extend the role that integrin α7 plays in cancer to the malignant transformation of pleural mesothelioma. Malignant pleural mesothelioma cells from patients were screened for their ability to migrate in cell culture and grouped as low or high motility cells [1] . These cells were then subjected to genome-wide transcriptome analysis, which identified differential expression of 139 genes between the two groups. The results showed significantly reduced ITGA7 transcript in cells from the high mobility group (Figure 1 ).
Epigenetic regulation of integrin 7 expression
Previous studies in prostate cancers, hepatocellular carcinomas, glioblastomas, and leiomyosarcomas revealed mutations in the ITGA7 gene [9] . In this study, the authors demonstrate hypermethylation of the ITGA7 promoter region in high mobility malignant pleural mesothelioma cells, indicating epigenetic suppression of integrin α7 gene expression [1] . To substantiate that loss of integrin α7 expression was the primary cause of the migratory phenotype, the authors forced expression of the ITGA7 gene and were able to show that restoring α7 expression inhibited migration of the cells. Thus, the findings [1] demonstrate a novel epigenetic mechanism of integrin α7 gene regulation that led to a highly motile cell phenotype (Figure 1 ).
Reduced ITGA7 expression correlates with a poor clinical outcome
To determine if loss of ITGA7 expression was associated with disease progression in malignant pleural mesothelioma, the authors compared ITGA7 promoter methylation with clinical outcomes. While normal plural cells exhibited varying levels of integrin α7, ITGA7 hypermethylation strongly correlated with poor prognostic outcomes in patients [1] .
Biomarker and therapy development for mesothelioma
The current treatment for malignant pleural mesothelioma is surgical intervention; however, this approach often results in recurrent tumour growth. Laszlo et al [1] identified a novel molecular mechanism by which mesothelioma transitions to malignant pleural mesothelioma that involves down-regulating expression of integrin α7. These cells are likely selected for their ability to rapidly migrate and move from the primary tumour site to distant locations (Figure 1 ). Increasing integrin α7 in these cells is one potential therapeutic option; however, since the ITGA7 promoter is hypermethylated in malignant pleural mesothelioma cells, drugs that target ITGA7 transcription in these cells are unlikely to be effective. In addition, because integrin α7 is found in many tissues and regulates complex cell signalling pathways, off-target drug activity in other tissues and cells in which the ITGA7 gene promoter is not methylated may be problematic, although this might be overcome by restricting drug delivery. A second pharmacological option may be to utilize therapeutics that inhibit the actions of methyltransferases and prevent hypermethylation of the integrin α7 promoter in mesothelioma cells to slow disease progression [10] . The use of integrin α7 enhancing drugs in combination with therapies that inhibit methyltransferases or demethylate the ITGA7 promoter may have efficacy 284 DJ Burkin and TM Fontelonga in the treatment of malignant pleural mesothelioma (Figure 1) . Further research will be required to develop these approaches and reduce the potential of unwanted side effects. Finally, since the authors show a strong correlation between ITGA7 promoter hypermethylation and clinical outcome [1] , this study suggests a diagnostic test may be developed that examines the methylation status of the ITGA7 promoter in biopsy samples that can be used to monitor disease progression in patients with mesothelioma.
